source
- Intercept’s next-generation FXR agonist INT-787 fails Phase 2 trial in alcohol-associated hepatitisIntercept Pharmaceuticals reported that its experimental FXR agonist INT-787 did not demonstrate efficacy in a Phase 2 study of patients with severe alcohol-associated hepatitis. The trial results…
- Supreme Court temporarily restores broad access to abortion pill mifepristoneThe Supreme Court issued an order on Monday that temporarily reinstates wide availability of the abortion medication mifepristone. The order follows a federal appeals court decision that had threat…